What are the side effects

Lifitegrast is a small molecule drug that belongs to the class of lymphocyte function-associated antigen-1 (LFA-1) antagonists. It is used for the treatment of dry eye disease, a condition that affects millions of people worldwide. The drug works by selectively binding to the intracellular adhesion molecule-1 (ICAM-1) and blocking the interaction between LFA-1 and ICAM-1, which leads to the reduction of inflammation in the eye. Lifitegrast is available in the form of an ophthalmic solution, which is administered topically to the affected eye.

What are the side effects of Lifitegrast?

Like all drugs, Lifitegrast may cause side effects in some people. The most common side effect of the drug is eye irritation, which occurs in about 5% of patients. Other common side effects include blurred vision, dysgeusia (taste disturbance), and reduced visual acuity. Some patients may also experience hypersensitivity reactions, such as itching, burning, and redness of the eye. If you experience any of these side effects, you should contact your doctor immediately.

Can Lifitegrast be used during pregnancy?

Lifitegrast has not been studied in pregnant women, and its safety during pregnancy is not known. Women who are pregnant or planning to become pregnant should talk to their doctor before using Lifitegrast.

Is Lifitegrast safe for children?

The safety and effectiveness of Lifitegrast in children under 18 years of age have not been established. Therefore, the drug should not be used in children.

Can Lifitegrast be used with other eye drops?

Lifitegrast can be used with other eye drops, but they should be administered at least 5 minutes apart. You should talk to your doctor if you are using any other eye drops before using Lifitegrast.

How long does it take for Lifitegrast to work?

The effect of Lifitegrast on the signs and symptoms of dry eye disease is usually seen within 2-4 weeks of treatment. However, some patients may take longer to respond to the drug.

Is a prescription required for Lifitegrast?

Yes, Lifitegrast is a prescription drug, and it can only be obtained with a valid prescription from a healthcare professional.

In summary, Lifitegrast is a small molecule drug that is used for the treatment of dry eye disease. The drug works by reducing inflammation in the eye and blocking the interaction between LFA-1 and ICAM-1. However, Lifitegrast may cause side effects in some people, such as eye irritation, blurred vision, and dysgeusia. The drug has not been studied in pregnant women and children under 18 years of age. If you have any questions or concerns about Lifitegrast, you should talk to your doctor.

Jiangsu Run'an Pharmaceutical Co. Ltd. is a pharmaceutical company that specializes in the research, development, and production of innovative drugs for the treatment of various diseases. Our mission is to improve the health and well-being of people around the world through our innovative and high-quality drugs. You can reach us at wangjing@ctqjph.com or visit our website at https://www.jsrapharm.com for more information.

10 Scientific Papers on Lifitegrast:

1. Holland EJ, et al. Lifitegrast for the treatment of dry eye disease: results of a Phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2016;123(11): 2201-2212.

2. Donnenfeld E, et al. Lifitegrast for the treatment of dry eye disease: a Phase III, randomized, double-masked, placebo-controlled trial (OPUS-2). Cornea. 2016;35(8): 1001-1008.

3. Tauber J, et al. Lifitegrast ophthalmic solution 5% versus placebo for treatment of dry eye disease: results of the randomized Phase III OPUS-1 trial. Ophthalmology. 2015;122(12): 2423-2431.

4. Sheppard JD, et al. Lifitegrast ophthalmic solution 5% for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Am J Ophthalmol. 2017; 177: 8-19.

5. Ousler GW, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2): 207-215.

6. McLaurin E, et al. Lifitegrast ophthalmic solution 5% for the treatment of dry eye disease: a review of clinical effectiveness and cost-effectiveness. CADTH Technol Overv. 2018;8(2): e011664.

7. Pflugfelder SC, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2004;111(4): 773-782.

8. Sheppard